INTERVIEW: GNT To Rise Again With New Clinical Development Strategy

GNT Pharma, which failed to progress its clinical pipeline amid global financial woes several years ago, aims to get back on its feet with the help of a new development strategy and improved regulations. The South Korean company's CEO sat down with PharmAsia News to talk about the first-in-class stroke therapy Neu2000 and what the company aims to achieve.